SEC Form 4 · accession 0001123292-17-000264
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Suzanne M. Hanlon
Officer — Sec, General Counsel & VP HR
Period of report
Jan 25, 2017
Accepted (ET)
Jan 26, 2017 · 4:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $18.22 | Jan 25, 2017 | A | 60,000 | A | — | Jan 25, 2027 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company.